amgen

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

The earnings crunch is in full swing this this week. Quarterly results are due from the likes of Caterpillar (NYSE: CAT), Exxon Mobil (NYSE: XOM), Procter & Gamble (NYSE: PG) and United Parcel Service (NYSE: UPS), from which analysts expect to see year-over-year earnings growth, as well as...

Piper Jaffray has published a report on Amgen (NASDAQ: AMGN) covering individual product lines. In the report, Piper Jaffray wrote, "Amgen reported 2Q earnings that were well above consensus expectations, with most major product lines coming in ahead and Epogen sales meeting Street forecasts. Both...

The earnings crunch continues this week even as the month of July winds to a close. Quarterly reports of note scheduled for the week include those from Netflix (NASDAQ: NFLX), United Parcel Service (NYSE: UPS), Exxon Mobil (NYSE: XOM), Starbucks (NASDAQ: SBUX), Merck (NYSE: MRK) and Dow Chemical (...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Goldman Sachs reiterated its Sell rating on Amgen (NASDAQ: AMGN). In today's trading, Amgen lost 0.31% of its value to trade around $58.47.

Oppenheimer is out with its report today on Amgen (NASDAQ: AMGN), maintaining Outperform. In a note to clients, Oppenheimer writes, "While the company is facing a number of regulatory and competitive headwinds, we believe revenues from Amgen's core franchises are nearing stabilization. We believe...

According to Jefferies, Amgen (NASDAQ: AMGN) estimates are maintained. Jefferies said that updated label removes a specific Hb target range (10-12 g/dL) and guides to individualize ESA therapy to reduce the need for red blood cell transfusions. Also, the label implies Hb target dose of 10-11 g/dL...